249 13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 13.2.2.1 US TO DOMINATE NORTH AMERICAN GLP-1 AGONISTS MARKET DURING FORECAST PERIOD 13.2.3.1 FAVORABLE FUNDING SCENARIO AND PRESENCE OF STRONG RESEARCH INFRASTRUCTURE TO SUPPORT MARKET GROWTH 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 13.3.2.1 EXPERTISE IN BIOTECHNOLOGY AND REPUTATION AS LEADING PHARMACEUTICAL MANUFACTURING HUB TO EXPEDITE MARKET GROWTH 13.3.3.1 GROWING R&D INITIATIVES FOR DEVELOPMENT OF GLP-1 AGONISTS DRUGS TO SUPPORT MARKET GROWTH 13.3.4.1 FAVORABLE REGULATORY SCENARIO AND STRONG RESEARCH INFRASTRUCTURE TO PROPEL MARKET GROWTH 13.3.5.1 PRESENCE OF KEY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO BOOST MARKET GROWTH 13.3.6.1 HIGH INCIDENCE OF DIABETES AND OBESITY TO AUGMENT MARKET ADOPTION OF GLP-1 THERAPEUTIC DRUGS 13.3.7.1 STRONG FOCUS ON PHARMACEUTICAL R&D TO SUPPORT MARKET GROWTH 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 13.4.2.1 INCREASING ENDORSEMENTS OF ANTI-OBESITY DRUGS BY CELEBRITIES TO DRIVE MARKET ADOPTION 13.4.3.1 HIGH DIABETIC POPULATION AND FAVORABLE REGULATORY SCENARIO TO AID MARKET GROWTH 13.4.4.1 GROWING DEMAND FOR COST-EFFECTIVE AND ACCESSIBLE ANTI-OBESITY MEDICATIONS TO AID MARKET GROWTH 13.4.5.1 SIGNIFICANT GOVERNMENT INVESTMENT IN OBESITY PREVENTION TO FUEL MARKET GROWTH 13.4.6.1 INCREASING STRATEGIC COLLABORATIONS IN OBESITY DRUGS TO PROPEL MARKET GROWTH 13.4.7 REST OF ASIA PACIFIC 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 13.5.2.1 INCREASING PARTNERSHIPS WITH GLOBAL PHARMACEUTICAL COMPANIES AND RISING DIABETES CASES TO DRIVE BRAZILIAN MARKET 13.5.3.1 GROWING DIABETES AND OBESITY PREVALENCE TO SUPPORT MARKET GROWTH 13.5.4 REST OF LATIN AMERICA 13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 13.6.2.1 KINGDOM OF SAUDI ARABIA 13.6.2.3 REST OF GCC COUNTRIES 13.6.3 REST OF MIDDLE EAST 13.7.1 GROWING HEALTHCARE AND LIFE SCIENCE INDUSTRY TO SUPPORT GROWTH 13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 14 COMPETITIVE LANDSCAPE Discover emerging leaders and strategic shifts shaping the GLP-1 agonists market dominance
In addition to protection of macrovascular complications of T2DM by DPP-4 inhibitors, including linagliptin [29, 43, 84, 117], emerging evidence from clinical studies conducted on small numbers of patients with T2DM reported improvement in microvascular function by linagliptin [30, 49,50,51]
Typical out-of-pocket cost: $350 to $500 per month $199 per month (generic Ozempic) at Universal Drugstore Patients may use discount cards such as GoodRx or SingleCare, but savings can vary depending on eligibility and pharmacy pricing
If you are ready to start a personalized weight loss program designed around your unique health profile, take the free assessment quiz
.png)
